👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Thermo Fisher Scientific to buy Olink in $3.1 billion deal

Published 10/17/2023, 08:52 AM
Updated 10/17/2023, 09:55 AM
© Reuters. FILE PHOTO: A company flag flies outside the offices of Thermo Fisher Scientific offices in Waltham, Massachusetts, U.S., August 2, 2023.     REUTERS/Brian Snyder/File Photo
TMO
-
B2INOK
-

(Reuters) -Thermo Fisher Scientific would acquire Olink Holding AB in a deal valued at $3.1 billion, the companies said on Tuesday, as the U.S. medical equipment maker seeks to boost its life sciences portfolio that helps drug discovery.

The deal lifted Olink's U.S.-listed shares nearly 67% in early trading, while shares of Thermo Fisher (NYSE:TMO) were down over 1%.

Thermo Fisher has been struggling with softening demand for its life sciences offerings, which includes discovery and production of new drugs and vaccines, as its biotech clients face a funding crunch.

Sweden-based Olink provides products and services for advanced analysis of proteins that are key markers of multiple diseases, which in turn help in drug discovery and development.

Olink's acquisition will help Thermo Fisher's customers in the biotech industry "to meaningfully accelerate discovery and scientific breakthroughs," Thermo Fisher CEO Marc Casper said.

The deal also includes net cash of about $143 million.

Thermo Fisher said it would pay Olink shareholders $26 per share, an about 74% premium to the U.S.-listed stock's closing price on Monday.

Thermo Fisher plans to fund the transaction using its cash on hand and debt financing, and expects the deal to be closed by mid 2024.

© Reuters. FILE PHOTO: A company flag flies outside the offices of Thermo Fisher Scientific offices in Waltham, Massachusetts, U.S., August 2, 2023.     REUTERS/Brian Snyder/File Photo

The deal is a good fit for Thermo Fisher and "checks the box strategically," Evercore ISI analyst Vijay Kumar wrote in a note.

Olink is on track to generate over $200 million in revenue next year and, as part of Thermo Fisher, is expected to grow mid-teens organically, the companies said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.